Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one of the most widely used drug combination in Africa, despite possible constraints with adherence and poor absorption due to inadequate nutrition, and a lack of pharmacokinetic and effectiveness data. METHODS: Within a trial of supervised versus unsupervised A/L treatment in a stable Ugandan Plasmodium falciparum transmission setting, plasma lumefantrine concentrations were measured in a subset of patients on day 3 (C [lum]day3) and day 7 (C [lum]day7) post-inclusion. Predictors of lumefantrine concentrations were analysed to show how both C [lum]day7 and the weight-adjusted lumefantrine dose affect 28-day recrudescence and re-infection risks. The implications of these novel findings are discussed in terms of the emergence of lumefantrine-resistant strains in Africa. RESULTS: C [lum]day3 and C [lum]day7 distributions among 241 supervised and 238 unsupervised patients were positively skewed. Unsupervised treatment and decreasing weight-adjusted lumefantrine dose were negatively associated with C [lum]day3. Unsupervised treatment and decreasing age showed strong negative associations with C [lum]day7. Both models were poorly predictive (R-squared < 0.25). There were no recrudescences in either arm, but decreasing lumefantrine dose per Kg resulted in up to 13-fold higher adjusted risks of re-infection. Re-infections occurred only among patients with C [lum]day7 below 400 ng/mL (p < 0.001). CONCLUSION: Maintaining the present six-dose regimen and ensuring high adherence and intake are essential to maximize the public health benefits of this valuable drug combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
Eastman, R. T., & Fidock, D. A. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2239 · Cited by 568
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0456-7 · Cited by 464
Banek, K., Lalani, M., Staedke, S. G., & Chandramohan, D. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-7 · Cited by 125
Faucher, J., Aubouy, A., Adeothy, A., Cottrell, G., Doritchamou, J., Gourmel, B., Houzé, P., Kossou, H., Amedome, H., Massougbodji, A., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/599378 · Cited by 61
“[24] reported that reinfections occurred only when day 7 lumefantrine levels were low.”
BackgroundBruxvoort, K., Festo, C., Cairns, M., Kalolella, A., Mayaya, F., Kachur, S. P., Schellenberg, D., & Goodman, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134275 · Cited by 37
Metadata
- Authors
- Checchi, F., Piola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., Ferradini, L., Taylor, W. R., & Guthmann, J.-P.
- Venue
- Malaria Journal
- Published
- 2006-07-19
- Volume
- 5
- Issue
- 1
- Pages
- 59-59
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2116913457
- Cited by
- 73
- References
- 0
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. https://app.cochat.ai/papers/10.1186/1475-2875-5-59
- The paper
- Checchi, F., Piola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., Ferradini, L., Taylor, W. R., & Guthmann, J.-P. (2006). Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malaria Journal. https://doi.org/10.1186/1475-2875-5-59
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.